. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Cancer. 2019 Sep 18;125(23):4148–4157. doi: 10.1002/cncr.32361

Table 2:

Summary of clinical trial results for first-line combination therapy in RCC. Data are not intended for cross-trial comparisons. n= number of patients assigned to treatment arm; mo=months; f/u=follow up

Study	Treatment	n	ORR (%)	CR (%)	Median PFS (mo)	Median f/u at PFS (mo)	Patients Alive (%)	Median f/u for survival (mo)
Checkmate 214³⁵	Nivolumab plus ipilimumab	550	39	9	12.4	25.2	83	12
Checkmate 214³⁵	Sunitinib	546	32	1	12.3	25.2	77	12
IMmotion 151³⁹	Atezolizumab plus bevacizumab	454	37	5	11.2	15	72.9	15
IMmotion 151³⁹	Sunitinib	461	33	2	8.4	15	69.4	15
KEYNOTE-426⁴⁰	Pembrolizumab plus axitinib	432	59.3	5.8	15.1	12.8	89.9	12.8
KEYNOTE-426⁴⁰	Sunitinib	429	35.7	1.9	11.1	12.8	78.3	12.8
Javelin Renal 101⁴¹	Avelumab plus axitinib	442	51.4	3.4	13.8	10.8	85.7	12
Javelin Renal 101⁴¹	Sunitinib	444	25.7	1.8	8.4	8.6	83.1	11.5